Hypersensitivity to the active substance or to any of the excipients listed in Description or to benzazepine or benzazepine derivatives (see Precautions).
Elevated liver enzymes and/or signs or symptoms of liver injury prior to initiation of treatment that meet the requirements for permanent discontinuation of tolvaptan (see Precautions).
Anuria.
Volume depletion.
Hypernatraemia.
Patients who cannot perceive or respond to thirst.
Pregnancy (see Use in Pregnancy & Lactation).
Breast-feeding (see Use in Pregnancy & Lactation).